Spruce Biosciences (NASDAQ:SPRB – Get Free Report) and iBio (NYSE:IBIO – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, risk and dividends.
Institutional & Insider Ownership
91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 6.9% of Spruce Biosciences shares are held by insiders. Comparatively, 2.8% of iBio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Spruce Biosciences and iBio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Spruce Biosciences | N/A | -305.39% | -168.01% |
| iBio | N/A | -73.15% | -45.51% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Spruce Biosciences | 1 | 4 | 3 | 1 | 2.44 |
| iBio | 0 | 0 | 3 | 0 | 3.00 |
Spruce Biosciences currently has a consensus target price of $178.88, indicating a potential upside of 114.48%. iBio has a consensus target price of $4.00, indicating a potential upside of 106.19%. Given Spruce Biosciences’ higher probable upside, analysts plainly believe Spruce Biosciences is more favorable than iBio.
Valuation & Earnings
This table compares Spruce Biosciences and iBio”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Spruce Biosciences | $4.91 million | 18.17 | -$53.04 million | ($85.00) | -0.98 |
| iBio | $500,000.00 | 87.25 | -$24.91 million | ($1.39) | -1.40 |
iBio has lower revenue, but higher earnings than Spruce Biosciences. iBio is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Spruce Biosciences has a beta of 3.46, suggesting that its share price is 246% more volatile than the S&P 500. Comparatively, iBio has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500.
Summary
Spruce Biosciences beats iBio on 7 of the 13 factors compared between the two stocks.
About Spruce Biosciences
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
About iBio
iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.
Receive News & Ratings for Spruce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spruce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
